You are here

Article Text

Article menu
Download PDFPDF
Editorial
Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?
  1. W Doehner,
  2. S D Anker*
  1. Division of Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany
  1. Correspondence to:
    Wolfram Doehner
    MD, PhD, Division of Applied Cachexia Research, Department of Cardiology, Charité, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany ; wolfram.doehnercharite.de

Abstract

A substantial body of evidence has accumulated to suggest a role for the xanthine oxidase metabolic pathway in the pathophysiology of chronic heart failure and other cardiovascular diseases

  • BNP, brain natriuretic peptide
  • CHF, chronic heart failure
  • NO, nitric oxide
  • XO, xanthine oxidase
  • allopurinol
  • heart failure
  • xanthine oxidoreductase

https://doi.org/10.1136/hrt.2004.057190

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • ↵* Also Department of Clinical Cardiology, National Heart & Lung Institute, Imperial College, London, UK

    Linked Articles

    • Miscellanea
      WEB TOP 10
      BMJ Publishing Group Ltd and British Cardiovascular Society
      Heart 2005; 91 1089-1089 Published Online First: 14 Jul 2005.